Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, November 1998, p. 2923-2931, Vol. 42, No. 11
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
The Epstein-Barr Virus Thymidine Kinase Does Not Phosphorylate
Ganciclovir or Acyclovir and Demonstrates a Narrow Substrate
Specificity Compared to the Herpes Simplex Virus Type 1 Thymidine Kinase
Erik A.
Gustafson,1,2,3
Antoinette C.
Chillemi,1
David R.
Sage,1,2 and
Joyce D.
Fingeroth1,2,3,*
Division of Infectious Disease, Dana-Farber
Cancer Institute,1
Beth Israel Deaconess Medical
Center,2 and
Harvard Medical
School,3 Boston, Massachusetts
Received 21 April 1998/Returned for modification 24 June
1998/Accepted 19 August 1998
The Epstein-Barr virus (EBV) thymidine kinase (TK) was expressed in
mammalian 143B TK
cells to investigate its substrate
specificity. The herpes simplex virus type 1 (HSV-1) TK was similarly
expressed for comparison. Both viral TKs conferred a
TK+ phenotype on 143B TK
cells. The
nucleoside analog ganciclovir (GCV) did not affect the growth of 143B
EBV TK or 143B TK
cells but effectively killed 143B HSV-1
TK cells. Furthermore, lysates of 143B EBV TK cells could not
phosphorylate GCV, which was confirmed by high-performance liquid
chromatography. EBV TK, HSV-1 TK, and EBV TK N
, a
truncated EBV TK missing 243 N-terminal amino acids, were purified as
fusion proteins expressed in bacteria, and all had TK activity. In
addition, EBV TK was observed to have a thymidylate kinase activity but
could not phosphorylate GCV, acyclovir, or 2'-deoxycytidine. In
competition assays, only nucleoside analogs of thymidine significantly
inhibited thymidine phosphorylation by EBV TK, with the following rank
order: 5-bromodeoxyuridine > zidovudine > stavudine > sorivudine. These results demonstrate that EBV TK substrate specificity
is narrower than those of alphaherpesvirus TKs and that thymidine
analogs may be the most suitable nucleoside antivirals to target the
enzyme. Clinical implications for gammaherpesviruses are discussed.
*
Corresponding author. Mailing address: Division of
Infectious Disease, Beth Israel Deaconess Medical Center, 330 Brookline Ave., HIM 353, Boston, MA 02215. Phone: (617) 667-0072. Fax:
(617) 975-5243. E-mail:
joyce_fingeroth{at}bidmc.harvard.edu.
Antimicrobial Agents and Chemotherapy, November 1998, p. 2923-2931, Vol. 42, No. 11
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Wang, F.-Z., Roy, D., Gershburg, E., Whitehurst, C. B., Dittmer, D. P., Pagano, J. S.
(2009). Maribavir Inhibits Epstein-Barr Virus Transcription in Addition to Viral DNA Replication. J. Virol.
83: 12108-12117
[Abstract]
[Full Text]
-
Gill, M. B., Kutok, J. L., Fingeroth, J. D.
(2007). Epstein-Barr Virus Thymidine Kinase Is a Centrosomal Resident Precisely Localized to the Periphery of Centrioles. J. Virol.
81: 6523-6535
[Abstract]
[Full Text]
-
Perrine, S. P., Hermine, O., Small, T., Suarez, F., O'Reilly, R., Boulad, F., Fingeroth, J., Askin, M., Levy, A., Mentzer, S. J., Di Nicola, M., Gianni, A. M., Klein, C., Horwitz, S., Faller, D. V.
(2007). A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood
109: 2571-2578
[Abstract]
[Full Text]
-
Guerreiro-Cacais, A. O., Uzunel, M., Levitskaya, J., Levitsky, V.
(2007). Inhibition of Heavy Chain and {beta}2-Microglobulin Synthesis as a Mechanism of Major Histocompatibility Complex Class I Downregulation during Epstein-Barr Virus Replication. J. Virol.
81: 1390-1400
[Abstract]
[Full Text]
-
Zhu, W., Burnette, A., Dorjsuren, D., Roberts, P. E., Huleihel, M., Shoemaker, R. H., Marquez, V. E., Agbaria, R., Sei, S.
(2005). Potent Antiviral Activity of North-Methanocarbathymidine against Kaposi's Sarcoma-Associated Herpesvirus. Antimicrob. Agents Chemother.
49: 4965-4973
[Abstract]
[Full Text]
-
Gill, M. B., Murphy, J.-E., Fingeroth, J. D.
(2005). Functional Divergence of Kaposi's Sarcoma-Associated Herpesvirus and Related Gamma-2 Herpesvirus Thymidine Kinases: Novel Cytoplasmic Phosphoproteins That Alter Cellular Morphology and Disrupt Adhesion. J. Virol.
79: 14647-14659
[Abstract]
[Full Text]
-
Gershburg, E., Pagano, J. S.
(2005). Epstein-Barr virus infections: prospects for treatment. J Antimicrob Chemother
56: 277-281
[Abstract]
[Full Text]
-
Staudt, M. R., Kanan, Y., Jeong, J. H., Papin, J. F., Hines-Boykin, R., Dittmer, D. P.
(2004). The Tumor Microenvironment Controls Primary Effusion Lymphoma Growth in Vivo. Cancer Res.
64: 4790-4799
[Abstract]
[Full Text]
-
Gill, M. B., Roecklein-Canfield, J., Sage, D. R., Zambela-Soediono, M., Longtine, N., Uknis, M., Fingeroth, J. D.
(2004). EBV attachment stimulates FHOS/FHOD1 redistribution and co-aggregation with CD21: formin interactions with the cytoplasmic domain of human CD21. J. Cell Sci.
117: 2709-2720
[Abstract]
[Full Text]
-
Feng, W.-h., Hong, G., Delecluse, H.-J., Kenney, S. C.
(2004). Lytic Induction Therapy for Epstein-Barr Virus-Positive B-Cell Lymphomas. J. Virol.
78: 1893-1902
[Abstract]
[Full Text]
-
Roychowdhury, S., Peng, R., Baiocchi, R. A., Bhatt, D., Vourganti, S., Grecula, J., Gupta, N., Eisenbeis, C. F., Nuovo, G. J., Yang, W., Schmalbrock, P., Ferketich, A., Moeschberger, M., Porcu, P., Barth, R. F., Caligiuri, M. A.
(2003). Experimental Treatment of Epstein-Barr Virus-associated Primary Central Nervous System Lymphoma. Cancer Res.
63: 965-971
[Abstract]
[Full Text]
-
Porcu, P., Eisenbeis, C. F., Pelletier, R. P., Davies, E. A., Baiocchi, R. A., Roychowdhury, S., Vourganti, S., Nuovo, G. J., Marsh, W. L., Ferketich, A. K., Henry, M. L., Ferguson, R. M., Caligiuri, M. A.
(2002). Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8+ T-cell restoration. Blood
100: 2341-2348
[Abstract]
[Full Text]
-
Marschall, M., Stein-Gerlach, M., Freitag, M., Kupfer, R., van den Bogaard, M., Stamminger, T.
(2002). Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy. J. Gen. Virol.
83: 1013-1023
[Abstract]
[Full Text]
-
Feng, W.-h., Israel, B., Raab-Traub, N., Busson, P., Kenney, S. C.
(2002). Chemotherapy Induces Lytic EBV Replication and Confers Ganciclovir Susceptibility to EBV-positive Epithelial Cell Tumors. Cancer Res.
62: 1920-1926
[Abstract]
[Full Text]
-
Lock, M. J., Thorley, N., Teo, J., Emery, V. C.
(2002). Azidodeoxythymidine and didehydrodeoxythymidine as inhibitors and substrates of the human herpesvirus 8 thymidine kinase. J Antimicrob Chemother
49: 359-366
[Abstract]
[Full Text]
-
Moore, S. M., Cannon, J. S., Tanhehco, Y. C., Hamzeh, F. M., Ambinder, R. F.
(2001). Induction of Epstein-Barr Virus Kinases To Sensitize Tumor Cells to Nucleoside Analogues. Antimicrob. Agents Chemother.
45: 2082-2091
[Abstract]
[Full Text]
-
Kira, T., Grill, S. P., Dutschman, G. E., Lin, J.-S., Qu, F., Choi, Y., Chu, C. K., Cheng, Y.-C.
(2000). Anti-Epstein-Barr Virus (EBV) Activity of beta -L-5-Iododioxolane Uracil Is Dependent on EBV Thymidine Kinase. Antimicrob. Agents Chemother.
44: 3278-3284
[Abstract]
[Full Text]
-
Gustafson, E. A., Schinazi, R. F., Fingeroth, J. D.
(2000). Human Herpesvirus 8 Open Reading Frame 21 Is a Thymidine and Thymidylate Kinase of Narrow Substrate Specificity That Efficiently Phosphorylates Zidovudine but Not Ganciclovir. J. Virol.
74: 684-692
[Abstract]
[Full Text]
-
Pilger, B. D., Perozzo, R., Alber, F., Wurth, C., Folkers, G., Scapozza, L.
(1999). Substrate Diversity of Herpes Simplex Virus Thymidine Kinase. IMPACT OF THE KINEMATICS OF THE ENZYME. J. Biol. Chem.
274: 31967-31973
[Abstract]
[Full Text]
-
Cannon, J. S., Hamzeh, F., Moore, S., Nicholas, J., Ambinder, R. F.
(1999). Human Herpesvirus 8-Encoded Thymidine Kinase and Phosphotransferase Homologues Confer Sensitivity to Ganciclovir. J. Virol.
73: 4786-4793
[Abstract]
[Full Text]